Researchers in Austria investigated whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome in patients with advanced serous ovarian cancer. Data from 191 patients … Continued
Dr. Coleman, a member of the Alliance’s Scientific and Medical Advisory Board, conducted an interview on ovarian cancer therapies for the Cancer Network. He discussed the heterogeneity of ovarian cancer, … Continued
Research published online last week in Nature Communications suggests that some of the cell lines most frequently used to study high-grade serous ovarian cancer (HGSOC) may not be the best. … Continued
In an article published last week in The Lancet, an international group of investigators examined whether ovarian cancer tumors’ expression of the progesterone receptor (PR) and estrogen receptor (ER) was associated … Continued
Women with a family history of breast cancer but no BRCA1/2 mutation were found to be at average risk for developing ovarian cancer. The prospective study of 8005 women from … Continued
In an interview, 3-time grantee Dr. Zhang discusses his research and what it means to receive an award from OCRF.
We recently returned from the annual meeting of the American Society of Clinical Oncology (ASCO), an annual event that gathers thousands of cancer researchers from around the world. Many new … Continued
In a unanimous ruling issued June 13, 2013, the US Supreme Court ruled that private companies do not have the right to patent human genes. In Association for Molecular Pathology et … Continued
Society for Nuclear Medicine and Molecular Imaging (SNMMI) Advocate Report from Laurel Pracht As a member of the SNMMI Advocate Advisory Board, formed in 2010 to better bridge the gap … Continued
Ruling Will Give Women More Options to Learn About Genetic Risk Washington, DC—The Supreme Court ruled today that a company cannot patent naturally occurring genes, including isolated gene segments, overturning … Continued
A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use. See the … Continued
In research presented at the American Society of Clinical Oncology meeting this week, researchers found that shortening the break between chemotherapy sessions improved quality of life for patients, without negatively … Continued
Get email updates about research news, action alerts, and ways to join the fight.
